A third FDA advisor has resigned complying with last week’s debatable sped up authorization of Biogen’s Alzheimer’s drug. For access to live as well as exclusive video from
Website trip: Liberty Health Sciences (CNSX: LHS). – end of the week doesn’t look helpful for capital admiration. – S&P graph. Macroeconomics and Cannabis Analysis with James &
Emerald Health Therapeutics (CVE: EMH) (OTCMKTS: EMHTF) (FRA: TBD) CEO Chris Wagner reviews their current offer to be part of the British Columbia retail market. Wagner explains that
